Sermorelin is a synthetic GHRH 1–29 analog that amplifies endogenous pituitary GH pulsatility at the GHRH-receptor step; Ipamorelin is a selective ghrelin-receptor (GHSR-1a) agonist that triggers a clean GH pulse via a parallel pathway. Both have zero human RCTs for body composition, anti-aging, or sleep efficacy, both are WADA-prohibited under S2, and neither is FDA approved.
Both peptides share a critical honest verdict: zero published human RCTs as of August 2026 for the indications most readers are evaluating. Sermorelin's peer-reviewed body of work is anchored in 1990s pediatric GH-deficiency diagnostic-stimulation trials (Sermorelin deep-dive) and one pharmacodynamic study in healthy adults — it tests acute GH release under controlled diagnostic conditions, not body composition, not anti-aging, not sleep. Ipamorelin's peer-reviewed body of work is the 1998 Raun healthy-volunteer pharmacodynamic study that established selective ghrelin-receptor agonism (Ipamorelin deep-dive) but no completed human RCTs for body composition, anti-aging, or recovery-sleep. This page synthesizes the existing deep-dives; it does not introduce new evidence. If you are evaluating either peptide for a clinical decision, the underlying deep-dives are the authoritative references.
Each row states a claim that is supported by a specific peer-reviewed citation. PMIDs link to the corresponding PubMed record — open any of them to verify the underlying study directly. Tier badges follow the four-tier evidence language used across all PeptideDecoded content (human RCT → human observational → animal/preclinical → mechanistic/anecdote).
| Claim | Sermorelin evidence | Ipamorelin evidence |
|---|---|---|
| Receptor target & mechanism class | Strong (mechanistic)GHRH 1–29 synthetic analog. Binds the pituitary GHRH receptor and amplifies endogenous GH pulsatility without replacing it. Receptor pharmacology well characterized. | Strong (mechanistic)Selective GHSR-1a (ghrelin-receptor) agonist. Triggers GH release via a parallel pathway with minimal cortisol / prolactin co-activation. PMID: 9783708 |
| GH pulsatility in healthy adults (pharmacodynamic baseline) | Established (human pharmacodynamic)Walker 1994 characterized Sermorelin-induced amplification of endogenous GH pulsatility in healthy adults at multiple doses. PMID: 7527273 | Established (human pharmacodynamic)Raun 1998 established selective GH-pulse profile in healthy volunteers relative to GHRP-6 and GHRP-2 controls. PMID: 9783708 |
| Pediatric GH-deficiency diagnostic stimulation | Established (human)Reutens 1996 characterized the GHRH 1–29 (Sermorelin) diagnostic-stimulation profile in GH-deficient children; established the pediatric GH-deficiency testing window. PMID: 8834260 | Not establishedNo diagnostic-stimulation programme for Ipamorelin. Novo Nordisk NNC 26-0161 targeted post-operative ileus, not GH deficiency testing. |
| Post-operative ileus programme | Not a Sermorelin indicationNo ileus programme for Sermorelin — its mechanism (GHRH-receptor amplification) targets the pituitary, not GI motility. | Exploratory (human, narrow indication)Novo Nordisk NNC 26-0161 Phase II programme explored post-operative ileus; results never published in a peer-reviewed venue. |
| Endogenous GH-pulse preservation vs replacement | Established (mechanistic)Sermorelin amplifies rather than replaces the natural pulse architecture — preserves endogenous GHRH output. PMID: 7527273 | Pharmacologically plausibleGHSR-1a agonism is parallel-pathway, not directly replacing GH pulses — but the parallel-pathway mechanism is downstream of GHRH-receptor signaling. PMID: 9783708 |
| Sleep architecture / slow-wave recovery | Not establishedNo published sleep-architecture studies for Sermorelin. Mechanistic claim only. | Mechanism onlyGH pulsatility → slow-wave sleep is mechanistic, not RCT-established. PMID: 9783708 |
| Body composition / fat loss / muscle gain | NoneGH elevation is a surrogate, not an outcome. Zero published human RCTs using body-composition endpoints for Sermorelin. | NoneGH elevation is a surrogate, not an outcome. Zero published human RCTs using body-composition endpoints for Ipamorelin. |
| Anti-aging / longevity outcomes | NoneGH-axis pharmacology is a surrogate, not an outcome. Zero published human RCTs for any longevity endpoint. Sermorelin withdrawn from US market 2008. | NoneGH-axis pharmacology is a surrogate, not an outcome. Zero published human RCTs for any longevity endpoint. |
| Human randomized controlled trial (any efficacy indication) | NoneZero published peer-reviewed human RCTs for adult GH-pulse support, body composition, anti-aging, or sleep efficacy as of August 2026. | NoneZero published peer-reviewed human RCTs for adult GH-pulse support, body composition, anti-aging, or sleep efficacy as of August 2026. |
| WADA status | Prohibited (S2 — peptide hormones / GH secretagogues, at all times) | Prohibited (S2 — peptide hormones / GH secretagogues, at all times) |
| FDA status | Not approved. Withdrawn from US market in 2008. No compounding monograph; subject to the July 2026 FDA reclassification review. | Not approved. No compounding monograph; subject to the July 2026 FDA reclassification review. |
Citations reused from the Sermorelin deep-dive and the Ipamorelin deep-dive — PMIDs are limited to the set already cited in the underlying deep-dives (PubMed identifiers 8834260, 7527273, 9783708) — no new citations introduced.
Three side-by-side cards for direct comparison. The "Route / dosing" rows reflect community-reported ranges from peptide forums and compounding pharmacies — they are not clinically validated dosing protocols, and no human trial supports them.
Three honest verdicts. Each mirrors the same evidence-gap framing used in the underlying deep-dives — choosing one peptide over another does not establish human efficacy for either, it only frames where the mechanistic rationale is strongest.
Sermorelin is the only candidate in this comparison with a pediatric diagnostic-stimulation history and a 1994 pharmacodynamic anchor in healthy adults (PMID: 7527273; PMID: 8834260) — the binding at the GHRH receptor and the amplification of the natural pituitary pulse architecture characterize Sermorelin's most-cited mechanistic appeal. That is a real, replicated pharmacological finding. It does not test the outcomes (body composition, recovery, anti-aging) driving current vendor interest. Caveats: Sermorelin was withdrawn from the US market in 2008; it is not approved and is subject to the July 2026 FDA reclassification review; zero published human RCTs using body-composition, anti-aging, or sleep endpoints.
Ipamorelin's distinguishing feature is its selective GHSR-1a agonism, established in the original Raun healthy-volunteer pharmacodynamic study (PMID: 9783708): clean GH pulses without meaningful cortisol or prolactin co-activation. That profile is what justifies its adoption in recovery-sleep protocols. Caveats: GH elevation is a surrogate, not an outcome — zero published human RCTs using body-composition, anti-aging, or recovery endpoints. GH pulse ≠ validated efficacy for any of these indications.
Combining Sermorelin and Ipamorelin is a common GH-axis stack protocol because the mechanisms are complementary, not redundant: Sermorelin amplifies the endogenous GHRH-receptor-driven pulse while Ipamorelin triggers a parallel-pathway GH signal (PMID: 9783708; PMID: 7527273). They hit different steps in the GH cascade — upstream pulse-amplification vs. downstream pulse-trigger. Caveats: the rationale is mechanistic complementarity with zero published human safety or efficacy data on the pair; both peptides are WADA S2-prohibited (positive test on either remains a positive test); Sermorelin was withdrawn from the US market in 2008; both peptides sit in regulatory gray zone subject to the July 2026 FDA reclassification review of peptide hormones.
"Evidence tier" is the most important field in every claim above. Two peptides can share a use case while having radically different evidence behind that use case. The badge colors map to the same four-tier language used across all PeptideDecoded deep-dives:
For deeper context on how to evaluate any peptide claim — peer review, COI checks, red flags, and a 5-question pre-purchase checklist — see How to Verify Peptide Claims and the Editorial Standards page.
This comparison is the synthesis. The full evidence reviews are the underlying references — open either one if you want to evaluate a specific claim, verify a citation, or read the COI disclosure in detail.
Competitive athletes (WADA S2 + S2): Sermorelin and Ipamorelin are both prohibited at all times under S2 (peptide hormones / GH secretagogues). A positive test for either results in a ban, and there is no Therapeutic Use Exemption (TUE) pathway for either compound. The WADA categorization is legally identical between Sermorelin and Ipamorelin.
Anyone seeking an FDA-approved therapy: neither peptide is approved for any human indication. Sermorelin was withdrawn from the US market in 2008. Ipamorelin has no compounding monograph and sits in regulatory gray zone subject to the July 2026 FDA reclassification review of peptide hormones. Both peptides are subject to that review. Stacking amplifies regulatory exposure without adding evidence.
Anyone needing proven human efficacy: zero published human RCTs for both peptides for adult body composition, anti-aging, or sleep efficacy as of August 2026. Community-reported outcomes are not clinical evidence. If you need a therapy with validated human efficacy, neither peptide is the right starting point — much less the combination.
This comparison page is a research summary, not medical advice. PeptideDecoded does not sell peptides, recommend vendors, provide dosing protocols, or make claims about safety or efficacy for any specific individual.
Work with a qualified physician who can evaluate your full medical history, current medications, and individual risk factors before making any decision about peptides — whether FDA-approved, compounded, or sold as research chemicals.